FDA Approves Updated Label for Nuvation Bio's IBTROZI with Extended Response Duration
The U.S. Food and Drug Administration has approved an updated label for Nuvation Bio's IBTROZI (taletrectinib). The update reflects a median duration of response of nearly 50 months in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer.
Nuvation Bio announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for its medication IBTROZI (taletrectinib). The updated drug label now includes extended data on the duration of response for patients.
The new information highlights a median duration of response of nearly 50 months among TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, according to data from the TRUST-I study. This approval was granted four months ahead of the Prescription Drug User Fee Act (PDUFA) date.
Nuvation Bio stated that the updated labeling does not introduce any changes to the safety sections of the drug's information. Longer follow-up did not identify any new safety signals related to the treatment. The approval signifies an expansion of the known efficacy of IBTROZI in a specific patient population.
IBTROZI is a targeted therapy used in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation. The updated information on response duration provides physicians and patients with more comprehensive data when considering treatment options for this condition.